Management of Jehovah's Witness patients with haematological problems

Blood Reviews

Volumn 18, Issue 3, 2004, Pages 211-217

  Nash, Michael J ^a,b   Cohen, Hannah ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gillick; Jehovah's Witness; Transfusion

Indexed keywords

ANTIFIBROTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 9; COLONY STIMULATING FACTOR 1; DESMOPRESSIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; POLYMERIZED HEMOGLOBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; TRANEXAMIC ACID;

ANEMIA; BLEEDING; BLOOD SAMPLING; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; ETHICS; HEMATOLOGIC DISEASE; HEMOPHILIA; HUMAN; JEHOVAH'S WITNESS; MEDICOLEGAL ASPECT; META ANALYSIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW;

EID: 3042713988     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(03)00065-1     Document Type: Article

References (59)

1. Marsh J.C., Bevan D.H. Haematological care of the Jehovah's Witness patient. Br. J. Haematol. 119:2002;25-37
2. Sharp D. Jehovah's Witnesses' blood policy. Lancet. 356:2000;8
3. Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. BMJ. 322:2001;37-39
4. Watchtower Bible and Tract Society. Questions from readers. Watchtower 2000;15:29-31
5. Murphy M.F., Wallington T.B., Kelsey P., et al. Guidelines for the clinical use of red cell transfusions. Br. J. Haematol. 113:2001;24-31
6. Weiskopf R.B., Viele M.K., Feiner J., et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 279:1998;217-221
7. Hebert P.C., Wells G., Blajchman M.A., et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N. Engl. J. Med. 340:1999;409-417
8. Kitchens C.S. Are transfusions overrated? Surgical outcome of Jehovah's Witnesses. Am. J. Med. 94:1993;117-119
9. Carson J.L., Poses R.M., Spence R.K., Bonavita G. Severity of anaemia and operative mortality and morbidity. Lancet. 1:1988;727-729
10. Viele M.K., Weiskopf R.B. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion. 34:1994;396-401
11. Ng K.O., Chow L.H., et al. Successful management of massive blood loss to extremely low hemoglobin in an elderly woman receiving spinal surgery. Acta Anaesthesiol. Sin. 38:2000;89-92
12. Howell P.J., Bamber P.A. Severe acute anaemia in a Jehovah's Witness. Survival without blood transfusion. Anaesthesia. 42:1987;44-48
13. Singla A.K., Lapinski R.H., Berkowitz R.L., Saphier C.J. Are women who are Jehovah's Witnesses at risk of maternal death? Am. J. Obstet. Gynecol. 185:2001;893-895
14. Suess S., Suess O., Brock M. Neurosurgical procedures in Jehovah's Witnesses: an increased risk? Neurosurgery. 49:2001;266-272
15. Turner M. The impact of new-variant Creutzfeldt-Jakob disease on blood transfusion practice. Br. J. Haematol. 106:1999;842-850
16. The Serious Hazards of Transfusion Steering Group. Serious hazards of transfusion annual report 2001-2002, 2003, ISBN 0953278956
17. Williamson L.M. Leucocyte depletion of the blood supply - how will patients benefit? Br. J. Haematol. 110:2000;256-272
18. Pamphilon D. Viral inactivation of fresh frozen plasma. Br. J. Haematol. 109:2000;680-693
19. Blajchman M.A. Immunomodulation and blood transfusion. Am. J. Ther. 9:2002;389-395
20. Vamvakas E.C., Blajchman M.A. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 97:2001;1180-1195
21. Pereira A. Deleterious consequences of allogenic blood transfusion on postoperative infection: really a transfusion-related immunomodulation effect? Blood. 98:2001;498-500
22. Eyster E., Bernene J. Nosocomial anemia. JAMA. 223:1973;73-74
23. Henry D.A., Moxey A.J., Carless P.A. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst. Rev. 2001;CD001886
24. Ekback G., Axelsson K., Ryttberg L., et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth. Analg. 91:2000;1124-1130
25. Laupacis A., Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth. Analg. 85:1997;1258-1267
26. Goodnough L.T., Monk T.G. Erythropoietin therapy in the perioperative setting. Clin. Orthop. 1998;82-88
27. Laupacis A., Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Transfus. Med. 8:1998;309-317
28. Marchetti M., Barosi G. Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery. Transfusion. 40:2000;673-681
29. Coyle D., Lee K.M., Fergusson D.A., Laupacis A. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics. 18:2000;161-171
30. Estrin J.T., Ford P.A., Henry D.H., Stradden A.P., Mason B.A. Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for a Jehovah's Witness. Am. J. Hematol. 55:1997;51-52
31. Pozza E., Ascanelli S., Bardella E., et al. Pancreatic surgery in Jehovah's Witnesses: the role of perioperative erythropoietin and intravenous iron. Surgery. 129:2001;120
32. Walton T., Macon E.J. Erythropoietin use in a Jehovah's Witness patient. Ann. Pharmacother. 36:2002;729-730
33. Pirker R., Smith R. Darbepoetin alfa: potential role in managing anemia in cancer patients. Expert Rev. Anticancer. Ther. 2:2002;377-384
34. Goodnough L.T., Brecher M.E., Kanter M.H., AuBuchon J.P. Transfusion medicine. Second of two parts - blood conservation. N. Engl. J. Med. 340:1999;525-533
35. Thomas M.J. Infected and malignant fields are an absolute contraindication to intraoperative cell salvage: fact or fiction? Transfus. Med. 9:1999;269-278
36. Bell K., Stott K., Sinclair C.J., Walker W.S., Gillon J. A controlled trial of intra-operative autologous transfusion in cardiothoracic surgery measuring effect on transfusion requirements and clinical outcome. Transfus. Med. 2:1992;295-300
37. Napier J.A., Bruce M., Chapman J., et al. Guidelines for autologous transfusion. II. Perioperative haemodilution and cell salvage. British Committee for Standards in Haematology Blood Transfusion Task Force. Autologous Transfusion Working Party. Br. J. Anaesth. 78:1997;768-771
38. Estella N.M., Berry D.L., Baker B.W., Wali A.T., Belfort M.A. Normovolemic hemodilution before cesarean hysterectomy for placenta percreta. Obstet. Gynecol. 90:1997;669-670
39. Winslow R.M. Blood substitutes: refocusing an elusive goal. Br. J. Haematol. 111:2000;387-396
40. Klein H.G. The prospects for red-cell substitutes. N. Engl. J. Med. 342:2000;1666-1668
41. Levy J.H. The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. Expert Opin. Biol. Ther. 3:2003;509-517
42. Anton N., Hitzler J.K., Kavanagh B.P. Treatment of life-threatening post-haemorrhagic anaemia with cell-free haemoglobin solution in an adolescent Jehovah's Witness. Br. J. Haematol. 118:2002;1183-1186
43. Levi M., Friederich P.W., Middleton S., et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat. Med. 5:1999;107-111
44. Takeuchi S., Utsunomiya A., Makino T., et al. Successful treatment for acute lymphoblastic leukemia without blood transfusion in a Jehovah's Witness. Am. J. Hematol. 60:1999;168-169
45. Kaito K., Kobayashi M., Sakamoto M., et al. Combination chemotherapy with G-CSF, M-CSF and EPO: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs. Acta Haematol. 100:1998;57-60
46. Kennedy G.A., Marlton P., Cobcroft R., Gill D. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia. Br. J. Haematol. 111:2000;1103-1105
47. d'Oiron R., Menart C., Trzeciak M.C., et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb. Haemost. 83:2000;644-647
48. Smith S. The role of the court in ethical decision making. Clin. Med. 1:2001;371-373
49. Hall D. Reflecting on Redfern: what can we learn from the Alder Hey story? Arch. Dis. Child. 84:2001;455-456
50. General Medical Council. Good medical practice, 2001
51. The Royal College of Surgeons of England. Code of practice for the surgical management of Jehovah's Witnesses, 1996
52. Vincent J.L. Transfusion in the exsanguinating Jehovah's Witness patient - the attitude of intensive-care doctors. Eur. J. Anaesthesiol. 8:1991;297-300
53. Howarth G. Changes in policy of refusal of blood by Jehovah's Witnesses. Refuse and decline have distinct meanings. BMJ. 322:2001;1123-1124
54. Marks P. The evolution of the doctrine of consent. Clin. Med. 3:2003;45-47
55. Knight B. Chapter 29: forensic medicine. Wetherall, Ledingham, Warrell Oxford textbook of medicine. 1996;4309-4317 Oxford University Press, Oxford
56. The Association of Anaesthetists of Great Britain and Ireland. Management of anaesthesia for Jehovah's Witnesses, 1999
57. Yate R.M., Milling M.A., McFadzean W. Treatment without consent: a medicolegal precedent. Lancet. 356:2000;69
58. Devereux J.A., Jones D.P., Dickenson D.L. Can children withhold consent to treatment? BMJ. 306:1993;1459-1461
59. Descombes H.M. Jehovah's Witnesses and blood transfusions. J. Med. Ethics. 27:2001;355